Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers
This study has been completed.
Sponsor:
Indiana University
Collaborators:
Information provided by (Responsible Party):
Zeruesenay Desta, Indiana University
ClinicalTrials.gov Identifier:
NCT01104376
First received: April 12, 2010
Last updated: April 8, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to see if administration of medicines and genetic differences affects the activity of a liver enzyme called CYP2B6 in healthy volunteers.
| Condition | Intervention |
|---|---|
|
Metabolism Pharmacokinetics |
Drug: Efavirenz and voriconazole |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Screening |
| Official Title: | Effect of Cytochrome P450 2B6 Genetic Polymorphism and Voriconazole on CYP2B6 Activity in Healthy Volunteers |
Resource links provided by NLM:
Further study details as provided by Indiana University:
Primary Outcome Measures:
- Measure CYP2B6 activity in vivo, using the metabolism and pharmacokinetics of efavirenz as a probe. [ Time Frame: 17 days ] [ Designated as safety issue: No ]
| Enrollment: | 60 |
| Study Start Date: | March 2010 |
| Study Completion Date: | April 2013 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: CYP2B6
CYP2B6*1/*1 , CYP2B6*1*6 and CYP2B6*6*6
|
Drug: Efavirenz and voriconazole
In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered. In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily.
Other Names:
|
Detailed Description:
The investigators will test the hypothesis that CYP2B6 genetic variants that show effects in vitro also influence the in vivo activity of CYP2B6 and its responsiveness to metabolic inhibition, using the metabolism of efavirenz (100 mg dose) as a marker of activity. The metabolism and pharmacokinetics of efavirenz will be determined in a total of 60 healthy volunteers with CYP2B6*1/*1, CYP2B6*1*6 and CYP2B6*6*6 at baseline (control) and after pretreatment with voriconazole.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Male or female subject between 18 and 55 years of age.
- Healthy individuals without any significant medical conditions as determined by a screening performed at University.
- Adherence to the study dietary and medication restrictions.
- Willingness to refrain from smoking or use of tobacco or marijuana one week before the start of the study and until completion of the study which will be a total of 17 days.
- Ability to commit the time requested for this study.
Exclusion Criteria:
- Underweight (weighs less than 50kg or 110lb) or over weight [body mass index (BMI) greater than 32].
- Drug or alcohol abuse (more than 3 alcoholic drinks per day on a regular basis).
- History of intolerance or allergic reaction (e.g. rash) to efavirenz and/or voriconazole.
- Significant health conditions such heart, gastrointestinal disorders, liver, or kidney diseases that may be exacerbated during the course of the study.
- History or current psychiatric illness (e.g. depression, anxiety, or nervousness).
- History or current eye sight disturbances (e.g. blurred vision).
- Serious infection within the last 2 weeks.
- Blood donation within the past two months.
- Screening results that do not fall in a healthy range.
- Regularly taking prescriptions (except hormonal agents, e.g. oral contraceptives), over-the-counter, herbal or dietary supplements, and alternative medications and are unable or unwilling to stop taking them one week before and during the study periods.
- Female with a positive pregnancy test.
- Female breastfeeding.
- Females of child-bearing potential who are unable or unwilling to either practice abstinence or use appropriate birth control up until the study completion, which will take a total of 17 days.
- Participation in a research study involving intensive blood sampling and/or have use study drugs in the last two months.
- Employed or student under supervision of any of the investigators of this study.
- Inability to state a good understanding of this study including risks and requirements, and inability to follow the rules of this study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01104376
Locations
| United States, Indiana | |
| Indiana University | |
| Indianapolis, Indiana, United States, 46202 | |
Sponsors and Collaborators
Indiana University
Investigators
| Principal Investigator: | Zeruesenay Desta, PhD | IU Department of Medicine/Division of Clinical Pharmacology |
More Information
No publications provided
| Responsible Party: | Zeruesenay Desta, Associate Professor of Medicine, Indiana University |
| ClinicalTrials.gov Identifier: | NCT01104376 History of Changes |
| Other Study ID Numbers: | 0808-16, R01GM078501 |
| Study First Received: | April 12, 2010 |
| Last Updated: | April 8, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Indiana University:
|
Cytochrome P450 CYP2B6 Voriconazole Efavirenz |
Pharmacokinetics Drug-Interactions Pharmacogenetics Healthy volunteers |
Additional relevant MeSH terms:
|
Efavirenz Voriconazole Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Therapeutic Uses Anti-HIV Agents Antifungal Agents 14-alpha Demethylase Inhibitors |
ClinicalTrials.gov processed this record on May 22, 2013